“Your genetic information should be controlled by you,” declares an advertisement for the American direct-to-consumer (DTC) genetic-testing firm 23andMe. Amid the current furor over electronic eavesdropping, the notion that individuals should decide who can access their personal data is particularly appealing.
But whether 23andMe is practicing what it preaches remains dubious, at best.
In fact, even some “techno-libertarians,” who believe that government should not regulate new developments in biotechnology, have supported the US Food and Drug Administration’s decision – outlined in a scathing letter to 23andMe CEO Anne Wojcicki last November – to prevent the firm from marketing its tests pending further scientific analysis.
Share this article
Read the full, original story: Genetics for the people: Nowhere in sight
